TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00635531

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam XR
Description: Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.
Study: NCT02996305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OV101 Regimen 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OV101 regimen 2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00388362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.
Study: NCT01448837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost/Timolol, 24-hour intraocular pressure monitoring
Description: Administered once in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost/Timolol, 24-hour intraocular pressure monitoring
Description: Administered once in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost, 24-hour intraocular pressure monitoring
Description: assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost, 24-hour intraocular pressure monitoring
Description: assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing
Study: NCT00209027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI scanning during behavioral reward task

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 30 mg by mouth once daily
Study: NCT02919956

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: An MRI scan takes pictures of the brain and heart using a magnet and radio waves. During scanning, measurements of oxygen delivery to the brain will be obtained (CMRO2) as well as evaluation of the heart as it relates to the brain. During the scan patients will be monitored for safety by ECG, blood pressure, television camera, pulse oximetry, and carbon dioxide measurements. Cardiac anesthesiologist and cardiologist will be present.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: An MRI scan takes pictures of the brain and heart using a magnet and radio waves. During scanning, measurements of oxygen delivery to the brain will be obtained (CMRO2) as well as evaluation of the heart as it relates to the brain. During the scan patients will be monitored for safety by ECG, blood pressure, television camera, pulse oximetry, and carbon dioxide measurements. Cardiac anesthesiologist and cardiologist will be present.
Study: NCT01225263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin, 20 mg, twice daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D3, 1000 IU, twice daily for 6 months
Study: NCT01275664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron Transdermal Patch
Description: Apply one patch to upper arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01826760

Intervention type: OTHER
Intervention: Using training and testing groups to construct ANN based on laboratory tests

Intervention type: OTHER
Intervention: Using training and testing groups to construct ANN based on laboratory tests
Study: NCT04130464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Infusion from ON-Q Pump
Description: Infusion of 0.2% ropivacaine at 8 mL/hour for 72 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Ketorolac Infusion from ON-Q Pump
Description: Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL/hour for 72 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Infusion from ON-Q Pump
Description: Infusion of 0.9% normal saline at 8 mL/hour for 72 hours
Study: NCT05137613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One visit root canal retreatment
Description: The teeth were treated in one-visit (OV) root canal retreatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation
Study: NCT02942082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACP oral care gel
Description: a desensitizing agent will be applied on tooth before and/or after bleaching

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: glycrin
Description: glycrin will be applied on tooth surface before and/or after bleaching
Study: NCT03487939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
Study: NCT03759704

Intervention type: DRUG
Intervention: Hyperpolarized 13CPyruvate
Description: Bolus injection of study drug during MRSI.
Study: NCT02182713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulfate/Ipratropium bromide
Description: Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol sulfate/Ipratropium bromide
Description: Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol 100 mcg per puff
Study: NCT05137613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two visit root canal retreatment
Description: The teeth were treated in two visit (TV) root canal retreatment. After completion of root canal instrumentation, calcium hydroxide (CH) paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
Study: NCT02182713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol 100 mcg per puff
Study: NCT02840149

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-DOTATATE PET/CT
Description: 68Ga-DOTATATE PET/CT scan
Study: NCT03402581

Intervention type: DEVICE
Intervention: c-mac laryngoscope
Description: type of laryngoscopes

Intervention type: DEVICE
Intervention: c-mac laryngoscope
Description: type of laryngoscopes
Study: NCT02567032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study: NCT03722628

Intervention type: DIAGNOSTIC_TEST
Intervention: MMP1 genotypes polymorphism
Description: Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis

Intervention type: DIAGNOSTIC_TEST
Intervention: MMP1 genotypes polymorphism
Description: Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis

Intervention type: DIAGNOSTIC_TEST
Intervention: MMP1 genotypes polymorphism
Description: Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis
Study: NCT01675115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNG-1
Description: BNG-1 3 grams TID for 4 weeks

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg QD for 4 weeks
Study: NCT03722628

Intervention type: DIAGNOSTIC_TEST
Intervention: MMP1 genotypes polymorphism
Description: Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis

Intervention type: DIAGNOSTIC_TEST
Intervention: MMP1 genotypes polymorphism
Description: Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis
Study: NCT00860431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: 6g/day (3 times a day)
Study: NCT03977298

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine
Study: NCT02188407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: MAC 3-5 V% during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol group (P group)- The group anaesthesied with propofol
Study: NCT04803162

Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution manometry
Description: The parameters of high-resolution esophageal manometry will be compared between EoE patients and controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution manometry
Description: The parameters of high-resolution esophageal manometry will be compared between EoE patients and controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum biomarkers
Description: The serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared between EoE patients and controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum biomarkers
Description: The serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared between EoE patients and controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastrointestinal Quality of Life index
Description: The Gastrointestinal Quality of Life index (GIQLI) will be compared between EoE patients and controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastrointestinal Quality of Life index
Description: The Gastrointestinal Quality of Life index (GIQLI) will be compared between EoE patients and controls.

Intervention type: DRUG
Intervention: Omeprazole 20 MG Oral Tablet
Description: The parameters of high-resolution esophageal manometry and serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared in the group of patients with EoE at enrollment in the project and after 3 months of treatment with PPIs.
Study: NCT02992964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
Study: NCT01878864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine lozenge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-adrenalin injection
Study: NCT01174849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix
Description: The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Description: The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMBO
Description: COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
Study: NCT03354338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intensive Periodontal treatment; Pre-medication with 2 gr of Placebo 1 hour before treatment
Study: NCT03271125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance
Description: Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
Study: NCT03820063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC-Pz
Description: * Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~* Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~* Carboplatin AUC 6mg•ml/min administered intravenously on day 1~* Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~* Treatment cycles are repeated on day 22~In case of non pCR; Adjuvant T-DM1, 3.6mg/kg Q 22 days, for 14 cycles.
Study: NCT01798628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
Study: NCT03977298

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CTG
Description: CTG will be positioned in the buccal aspect of the peri-implant tissue
Study: NCT04189757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study: NCT04356027

Intervention type: PROCEDURE
Intervention: ICA (Invasive Coronary Angiography)
Description: Patients will undergo a Pre-PCI Angiography

Intervention type: PROCEDURE
Intervention: OCT
Description: OCT pullback images will be collected pre-PCI and (optional) post-PCI procedure

Intervention type: PROCEDURE
Intervention: FFR
Description: FFR will be measured
Study: NCT01798628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
Study: NCT04356027

Intervention type: OTHER
Intervention: VFR Analysis
Description: VFR will be calculated offline using the OCT pullback images
Study: NCT01798628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: abiraterone acetate
Description: 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
Study: NCT01393951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: subcutaneous and intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: subcutaneous and intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: subcutaneous and intramuscular
Study: NCT02500342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Study: NCT00443287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ataciguat (HMR1766)
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ataciguat (HMR1766)
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ataciguat (HMR1766)
Description: oral administration
Study: NCT02665780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal debridement
Description: teeth cleaning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetylpyridium chloride
Description: mouthrinse
Study: NCT00443287

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: oral administration
Study: NCT01524705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Glargine-injectable, variable, once daily (QD), 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Glargine-injectable, variable, once daily (QD), 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin-oral, up to 1000mg, twice daily (BID), 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin-oral, up to 1000mg, twice daily (BID), 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prandial insulin
Description: Aspart or glulisine or lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Injectable, 5mcg, twice daily (BID), 6 months